Lupin Dental raises €15M to put veneer preparation in a robot

Why it matters

Lupin Dental is testing whether two specialists' clinical technique can become a repeatable hardware product for ordinary practices. Regulatory progress has moved that thesis beyond the lab; adoption and clinic economics are the next test.

Dr. Stefen Koubi and Dr. Galip Gurel, two aesthetic dentists who spent decades refining and teaching veneer preparation, have closed a €15 million Series A for their Montpellier-based Lupin Dental, according to EU-Startups' August 28th report.

Fynveur led the financing with €10 million, according to the financing report. Existing shareholders and private investors also participated, while a loan from Bpifrance supplemented the round. The financing disclosure does not specify whether that debt is included in the €15 million headline. Fynveur adviser Invus will take a Lupin Dental board seat.

The investment backs a specific attempt to productize clinical expertise. Koubi and Gurel have built careers around aesthetic dentistry, training other practitioners in techniques that can be difficult to reproduce consistently. Lupin Dental is their effort to encode those techniques into planning software and a supervised robotic workstation.

Koubi graduated from the Faculty of Dental Surgery in Marseille in 1998 and has taught conservative and restorative dentistry there since 2008. He founded L'Institut de la Facette, a training center devoted to veneers, smile design and restorative dentistry, in 2013. Gurel graduated from Istanbul University's dental school in 1981, studied prosthodontics at the University of Kentucky and founded the Turkish Academy of Aesthetic Dentistry.

Their backgrounds explain Lupin Dental's starting point. Koubi and Gurel were already trying to make aesthetic procedures teachable before they began trying to automate them.

Encoding a clinical craft

Lupin Dental describes the Lupin Robotic System as a "digital version" of the founders' intellectual and manual expertise. A dentist uses its software to design the intended smile and generate a tooth-preparation plan. The robotic workstation then removes tooth material according to that plan, under the dentist's supervision. The dentist remains responsible for completing the restoration and bonding the veneers.

That distinction matters. Lupin Dental is selling supervised automation for a tightly defined part of a procedure, rather than an autonomous replacement for a dentist. The initial application is minimally invasive preparation for porcelain laminate veneers, where small variations in how much enamel is removed can affect the restoration and its bond to the tooth.

The founders' commercial argument is that software and robotics can let less-specialized dentists reproduce procedures that previously depended heavily on an experienced practitioner's hand. Lupin Dental also says its workflow can preserve more enamel and reduce a multi-visit treatment to one appointment. Those clinical and productivity benefits remain Lupin Dental's claims, and broader evidence will be needed as deployment grows.

Early clinical evidence, with a small denominator

Lupin Dental announced its first clinical use in Pune, India, on February 7th, 2025. At that point, Lupin Dental said six patients had been treated in an ongoing post-market study.

A prospective study published later in 2025 covered 12 patients and 52 teeth. The researchers scanned the prepared teeth and compared them with the digital treatment plans. Root mean square errors centered around 0.15 millimeters, with results ranging from 0.04 millimeters to 0.26 millimeters.

The study offers an early measure of repeatability, though its 12-patient sample remains narrow. It tested how closely the robot followed its plans rather than establishing superiority over skilled dentists. Koubi and Gurel were among the study's authors, giving Lupin Dental direct clinical involvement in the evidence supporting its system.

Lupin Dental moved from that clinical study to its first commercial installation in India in November 2025. The system was placed at Pharande Dental Hospital in Pune. Lupin Dental licenses the technology to Dolphin Lifesciences, which manufactures and distributes it in India as the Dolphin Robotic Dental System.

On June 18th, 2026, Lupin Dental received UKCA certification, permitting commercialization in Great Britain. Lupin Dental does not have clinical clearance in the United States or the European Union, leaving two of the largest medical-device markets outside its current commercial footprint.

A surgical robotics operator takes the chair

Lupin Dental's founders supplied the clinical method. CEO Paul Roberts brings experience turning regulated robotics into a medical-device business.

Roberts previously co-founded CMR Surgical, the British developer of the Versius surgical robot. He is a Cambridge-trained engineer who worked on embedded systems before CMR Surgical. Roberts has argued that engineers cannot develop effective medical products in isolation and that clinicians need to shape the product from the beginning. Lupin Dental follows that structure unusually literally: its core product is built around procedures developed by its founders in their own dental practices.

Lupin Dental has also added operators with experience beyond clinical dentistry. Michel Mayer, a former chairman and CEO of Freescale Semiconductor, became board chairman in February. Philippe Veran, founder and CEO of dental-products manufacturer Biotech Dental, joined as a director. Invus' new board role adds an investor representative as Lupin Dental moves from regulatory milestones toward wider deployment.

Lupin Dental says it plans to expand partnerships with academic institutions, medical organizations, individual dentists and dental service organizations. That sales strategy gives the Series A a clear job: support the regulatory, manufacturing, training and service infrastructure required to place hardware in clinics.

Dental robots are moving beyond implants

Dental robotics has largely concentrated on implant surgery. Neocis, for example, developed the FDA-cleared Yomi system to guide implant placement and bone reduction. Neocis says Yomi passed 100,000 implant placements in 2025 and launched its next-generation Yomi S platform that November.

Restorative dentistry is attracting a separate group of developers. Perceptive is developing a robotic system for procedures including crown preparation, paired with optical coherence tomography and automated treatment planning. Perceptive says its prototypes are not cleared by the US Food and Drug Administration or available for sale in the United States.

Lupin Dental's focus on veneer preparation gives Koubi and Gurel a narrower entry point, rooted in a procedure they have practiced and taught for years. It also places the burden of proof on a market associated with elective aesthetic work, where clinics will weigh precision against the price, training requirements and utilization of a robotic workstation.

The Series A moves that bet into its commercial phase. Koubi and Gurel have shown that their technique can be represented as a digital plan and executed robotically in a small clinical population. Lupin Dental must now prove that ordinary dental practices can use the system safely, repeatedly and often enough to justify putting a robot beside the dentist's chair.